An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS) First published 24/05/2024 Last updated 24/10/2025 EU PAS number:EUPAS1000000169 Study Planned